Backgrounds/Aims: Compared with a single urinary biomarker, a composite of multiple urinary biomarkers may be more helpful for differentiating tubulointerstitial inflammation from interstitial fibrosis/tubular atrophy (IFTA) in kidney allografts. Methods: In this cross-sectional cohort study, we collected urine samples from 115 patients with for-cause biopsy, 53 patients with stable allografts, and 50 living kidney donors. We measured the urinary levels of transglutaminase 2 (TG2), syndecan-4 (SDC4), alpha 1 microglobulin (A1M), interferon-inducible protein 10 (IP-10), interleukin 6 (IL-6), and monocyte chemoattractant protein-1 (MCP-1). Results: The for-cause biopsy group showed significantly higher levels of logeTG2/Cr, logeA1M/Cr, logeIL-6/Cr, and logeMCP-1/Cr compared with other groups. In the for-cause biopsy group, logeTG2/Cr level was positively correlated with the severity of IFTA. After adjusting for age, sex, body mass index, diabetes, hypertension, cardiovascular disease, and the interval between kidney transplant and biopsy, TG2 and the interval between transplant and biopsy were significantly correlated variables for the severity of IFTA. Regarding tubulointerstitial inflammation, Body mass index, TG2, SDC4, and IP-10 were positively-correlated variables, and MCP-1 and the interval between transplant and biopsy were negatively-correlated variables. Conclusions: Our results show that post-transplant urinary levels of TG2, SDC4, MCP-1 and IP-10 may be a useful biomarker for tubulointerstitial inflammation and IFTA. (Ann Hepatobiliary Pancreat Surg 2018;22:310-320)
INTRODUCTION
Reliable biomarkers are crucial for timely assessment of conditions of patients, especially those who have just received organ transplants and are under risk of acute rejection. 1 Under the current standard of care for immunosuppression, acute rejection occurs in about 15-20% of patients who undergo kidney transplantation. Acute rejection is diagnosed by increase of serum creatinine or development of newly onset proteinuria, and is further confirmed by invasive needle biopsy. 2 However, in a subset of patients with subclinical acute rejection, no increase in serum creatinine or proteinuria can be observed. 3 Needle biopsy has become safer and its interpretation has been standardized; however, needle biopsy still carries the risk of post-biopsy bleeding, which can ultimately lead to graft loss. Moreover, biopsy interpretation is subject to sampling errors as well as inter-observer variability. 4 Moreover, systematic review or meta-analysis of biopsy studies are generally unfeasible due to recurring revisions of the diagnostic criteria every two years, which entail non-interconvertible histology classifications. 5 In addition, the predictive power of renal core biopsy has been shown to be poor. 6 In case of allograft rejections, abnormalities in immune response appear at the molecular level before becoming apparent at the histological level. 7 Therefore, there is a need for the development of noninvasive molecular biomarkers with high reliability and predictive power for early diagnosis and monitoring of any clinical condition after kidney transplantation. [8] [9] [10] Unlike interstitial fibrosis /tubular atrophy (IFTA), tubulointerstitial inflammation is a reversible condition of kidney allograft if early diagnosis and subsequent treatment is given. Therefore, it is important to distinguish tubulointerstitial inflammation from fibrosis. Several urinary biomarkers such as transglutaminase-2 (TG2) have been used for assessment of renal fibrosis 11, 12 as well as inflammation 13, 14 in kidney allografts. In the current study, we aimed to verify urinary biomarkers that enable distinction between tubulointerstitial inflammation and IFTA.
MATERIALS AND METHODS

Study population
From July 2015 to July 2017, a total of 210 kidney transplant recipients (aged 17 to 77 years) who were at least 6 months post kidney transplantation were asked to be enrolled in this study when they visited our center for regular check-up or for-cause allograft biopsy. After an informed consent was obtained, urine specimens were collected at the time of check-up or 2-3 hours before the for-cause biopsy. In addition, a total of 50 living kidney donors were enrolled in this study and urine specimens were collected just before donor nephrectomy. A total of 260 urine specimens were collected from the 260 patients for quantitative analysis of candidate biomarkers.
Recipients without for-cause biopsy were considered to have stable graft function if their average serum creatinine level was less than or equal to 2.0 mg/dL (180 mol/L) at the time of enrollment and was within 120% of the baseline value over the previous 6 months, there was no treatment for acute rejection, and no evidence of cytomegalovirus (CMV) or polyomavirus type BK (BKV) infection. 13 This study was performed after receiving approval from the institutional review board of Asan Medical Center (approval number: 2015-0758), and all patients provided written informed consent.
Urine sample collection and storage Urine sample (35-50 ml) was collected from each patient. For each urine specimen, 0. For-cause allograft biopsy and matched urine specimens A total of 123 patients had for-cause biopsy at the time of enrollment. Urine specimen was collected 2-3 hours before biopsy. At least seven glomeruli and one artery were included in all biopsies, which was adequate to diagnose and categorize rejection.
Among those biopsies, eight were diagnosed as polyomavirus type BK nephropathy and were excluded to 
RESULTS
Patients
This cross-sectional cohort study was conducted from (Fig. 1) .
Participant characteristics are shown in Table 1 .
Compared with the two recipient groups, living kidney donors were younger and had higher body mass index. In addition, serum creatinine in recipients with for-cause biopsy was significantly higher compared with other groups at the time of enrollment. There was no significant difference in the baseline characteristics between recipients with for-cause biopsy and those with stable graft function, except for higher serum creatinine level in those with for-cause biopsy.
One hundred and fifteen for-cause biopsies were analyzed in this study (Table 2 ). Sixteen patients ( 
Comparison of urinary biomarkers among the three groups
We quantified the level of each biomarker using ELISA kit or cytometric bead array flexset kit in each urine sample. TG2, SDC4, A1M, IL-6, and MCP-1 were significantly higher in the for-cause biopsy group compared with the other two groups ( Fig. 2A-C, 2E, F) . There was no significant difference in the level of IP-10 between the for-cause biopsy group and the stable graft function group, while the level of IP-10 in the for-cause biopsy group was significantly higher compared with that in the living kidney donor group (Fig. 2D) .
Comparison of urinary biomarkers according to the degree of interstitial fibrosis and tubular atrophy
The levels of each biomarker were quantified according to the degree of IFTA in recipients with for-cause biopsy.
Of the 115 recipients with for-cause biopsy, minimal (IFTA 0), mild (IFTA 1), and moderate-to-severe (IFTA 2) degree of IFTA were diagnosed in 12, 50, and 53 recipients, respectively. Severity of IFTA degree in the for-cause biopsy showed positive correlation with urinary TG2 level (Fig. 3A) . The level of A1M was significantly higher in recipients with moderate-to-severe IFTA compared with those with mild IFTA (Fig. 3C ). There was no significant correlation between the degree of IFTA and the levels of other candidate biomarkers (Fig. 3B , D-F). 
Comparison of urinary biomarkers between recipients with and without rejection
Of the 115 recipients with for-cause biopsy, 99 recipients were diagnosed with T-cell-mediated or antibodymediated rejection, whereas 16 recipients showed no evidence of rejection. When we compared the levels of biomarkers between recipients with and without rejection, the levels of TG2 and SDC4 were significantly higher in those with biopsy-proven acute rejection (Fig. 4A, B) . The level of A1M was higher in those with biopsy-proven acute rejection with marginal significance (Fig. 4C ). There was no significant difference in the levels of IP-10, IL-6, and MCP-1 between the two groups ( Fig. 4D-F with IFTA (ct+ci scores) ( Table 3) . Regarding tubulointerstitial inflammation (t+i scores), body mass index, loge (TG2/Cr), loge (SDC4/Cr), and loge (IP-10/Cr) were positively-correlated factors, whereas loge (MCP-1/Cr) and the interval between transplant and for-cause biopsy were negatively-correlated factors (Table 4) . There was no significant factor that represented glomurulitis/peritubular capillaritis (g+ptc scores). Most studies on diagnostic biomarkers used single non-invasive urinary molecules to assess ongoing acute rejection1. Hricik et al. 17 suggested that urinary CXCL9 mRNA and CXCL9 protein were useful for diagnosing acute rejection. According to Ho et al., 18 urinary matrix metalloproteinase-7 was elevated in renal allograft in- TG2 is a member of the transglutaminase enzyme family, and is involved in various biological functions such as angiogenesis, 20 apoptosis, 21 cell differentiation, 22 and wound healing. 23, 24 We have previously reported that TG2
DISCUSSION
is potentially involved in the stabilization of extracellular We also identified IP-10 as a significant urinary biomarkers for tubulointerstitial inflammation; this is consistent with the results of the study by Suthanthiran et al., in which IP-10 mRNA level in urinary cells contributed to the molecular signature for acute cellular rejection in kidney allografts. 13 We also verified urinary A1M and MCP-1 in kidney transplant recipients because they have been reported to be associated with the severity of tubulointerstitial fibrosis. 12 In a condition of renal tubule dysfunction, urinary A1M was elevated because proximal tubular reabsorptive capacity was decreased 26 and higher urinary A1M was correlated with IFTA on biopsy. analyses are relatively small suggesting that those models do not have enough predictive value. We also lack data from an external subset of cohort to validate our results.
In spite of several limitations, this study is worthy in that it revealed the association between a composite of urinary biomarkers and tubulointerstitial pathologic findings.
In conclusion, we have shown that a composite of urinary biomarkers including TG2, SDC4, IP-10, and MCP-1 proteins enables distinction between tubulointerstitial inflammation and IFTA. Validation of our results in a larger external cohort may provide a means of assessing immune status in kidney allograft recipients while minimizing the need for an invasive biopsy.
